
LC865
A novel long-acting metabolic research candidate. Published literature is minimal; included for exploratory research.
Read the LC865 research guide→Low stock, order soon
✓ 100% purity-match & safe-arrival guarantee
✓ Orders placed before 2:00 PM CT on a business day ship the same day.
✓ Free shipping over $200. One discount per order.
- Best value!Make this a kitLC865 + 3 mL BAC water + 10 syringes + 10alcohol pads — pads free, water & syringes 25% offStarting at$204.11$212.14
- Bacteriostatic Water0.9% benzyl alcohol water for reconstitution, sold as a single vial.$13.14
- Insulin Syringes31G 0.5 mL sterile syringes, sold in packs of 10, 100, or 300.$7
- Alcohol Prep Pads70% isopropyl alcohol pads, sold in packs of 10 or 200.$3
Molecular specification
- Molecular formula
- Not published
- Molecular weight
- ~4,900 g/mol (estimated)
- CAS number
- Not assigned (novel)
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 98.5%
- Elimination half-life
- No established PK
Mechanism & published research
Reported as a long-acting incretin-class agonist; mechanism details are not yet published.
Honest note on evidence: No peer-reviewed literature is currently available on this compound. It is offered strictly as a novel research material; no efficacy, mechanism, or safety is claimed.
Descriptions summarize existing published research and are not claims about outcomes from use. Every citation states its study type and population.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Retatrutide | Status | Retatrutide is well-characterized; LC865 is exploratory. |
Reconstitution
Concentration math only: add bacteriostatic water to the vial and the resulting concentration is shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Reviews
Reviews are collected post-delivery and screened to exclude any human-use or dosing-outcome claims before publication. They speak to product quality, shipping, and COA accuracy.
“Uncommon compound, but the COA was still per-lot and verified. That consistency is the point.”
Product FAQ
Why is there no evidence section?+
Because none is published. We state that plainly rather than pad the page, honest thinness is the policy.
Related compounds

Retatrutide
Triple GLP-1 / GIP / glucagon receptor agonist under study.

Tirzepatide
Dual GIP / GLP-1 receptor agonist, extensively studied.

Semaglutide
GLP-1 receptor agonist with a deep clinical literature.

Cagrilintide
Long-acting amylin analog studied with incretins.